We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Assay Targets Antibiotic Resistance with Pathogen Identification

By LabMedica International staff writers
Posted on 18 Feb 2019
A rapid diagnostic device has been developed to detect and identify the source of an infection in less than one hour. More...
The proprietary DNA-based technology has the potential to revolutionize infection control by providing a POC, inexpensive, rapid diagnosis of pathogens in humans, animals and agriculture.

The C-AST assay is being developed in tandem with the CAPTURE pathogen identification assay, which stands for confirm active pathogens through an amplified RNA expression platform. The CAPTURE assay identifies bacterial or fungal pathogens' RNA in liquid samples, including blood, urine, saliva, and other types, with a "universal fluorescent marker," applying the firm's proprietary array using a machine-learning algorithm.

Earlier this month, GeneCapture scientists presented data collected from the functioning prototype system for its collaborators at the University of Alabama (Huntsville, AL, USA). They tested four antibiotics: ampicillin (AMP), amoxicillin/clavulanate (AMC), trimethoprim/sulfamethoxazole (SXT), and ciprofloxacin (CIP), against the nine pathogens responsible for most UTI cases. The group organisms include strains of species like Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Staphylococcus aureus.

The scientists initially evaluated 70 runs comparing 181 drug exposures to no-drug controls. They then evaluated 25 subsequent assays against culture results, focusing on AMP, AMC, SXT, and CIP, with most being tested in duplicate or triplicate. The group did not encounter false resistances or false sensitivities using the drugs. They also emphasized that the C-AST assay performed identically to culture results but in a much shorter period of time. The C-AST assay can test the effectiveness of various antibiotics against pathogens in between 5 and 75 minutes.

Peggy L. Sammon, co-founder and the CEO of GeneCapture, said, “We realized that for most infections, knowing the identity of the organism wasn't enough, so we developed the C-AST assay to give us information about the right drugs to use once CAPTURE has identified an organism. Knowing the type of organism and its concentration allows the C-AST assay to quickly analyze which antibiotics are sensitive or resistant."

Related Links:
University of Alabama


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.